Amplify Weight Loss Drug & Treatment ETF (THNR)

NYSEARCA: THNR · IEX Real-Time Price · USD
26.95
-0.05 (-0.18%)
Jul 15, 2024, 12:58 PM EDT - Market open
-0.18%
Assets $3.21M
Expense Ratio 0.59%
PE Ratio 34.69
Shares Out 120,000
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date n/a
Payout Ratio n/a
1-Year Return n/a
Volume 2,802
Open 27.07
Previous Close 26.99
Day's Range 26.92 - 27.07
52-Week Low 24.92
52-Week High 27.07
Beta 0.21
Holdings 29
Inception Date May 21, 2024

About THNR

Fund Home Page

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

Asset Class Equity
Region Global
Stock Exchange NYSEARCA
Ticker Symbol THNR
Index Tracked VettaFi Weight Loss Drug Index

Top 10 Holdings

71.00% of assets
Name Symbol Weight
Eli Lilly and Company LLY 15.29%
Novo Nordisk A/S NVO 13.69%
AstraZeneca PLC AZN 6.98%
Chugai Pharmaceutical Co Ltd 4519.T 5.55%
Amgen Inc. AMGN 5.31%
Pfizer Inc. PFE 4.99%
Roche Holding AG ROG.SW 4.94%
FUJIFILM Holdings Corp 4901.T 4.93%
Merck & Co., Inc. MRK 4.71%
West Pharmaceutical Services, Inc. WST 4.61%
View More Holdings

News

SILJ, HACK, THNR: Trends in Thematic Investing

Amplify Junior Silver Miners ETF (SILJ) is up 28% year-to-date. Christian Magoon discusses the outlook for cybersecurity stocks, as Amplify's Cybersecurity ETF (HACK) is up 8% year-to-date.

Other symbols: HACKSILJ
4 days ago - Schwab Network

Top Themes in the First Half of 2024: Crypto, Chips, Ships & Silver

After a torrid risk-on run in the first quarter of 2024, markets cooled off a bit but ended the half still positive with mid-double-digit returns. Technology themes such as cryptocurrency and artifici...

12 days ago - ETF Trends

Why Investors Haven't Feasted on Two New Weight-Loss ETFs

Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.

Other symbols: OZEM
20 days ago - Investopedia

Finding Opportunity in Unloved Healthcare ETFs

Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?

6 weeks ago - ETF Trends

Amplify Debuts New Weight Loss Drug ETF

On Tuesday, Amplify entered the weight loss ETF space with the launch of the Amplify Weight Loss Drug & Treatment ETF (THNR). THNR operates with a net expense ratio of 0.59%.

7 weeks ago - ETF Trends